Biopharma firms must diversify CDMO partnerships to avoid costly delays: Shilpa Biologicals MD
Madhav Bhutada says overdependence on large CDMOs and delayed engagement can increase development costs by up to 40% and slow clinical progress
Madhav Bhutada says overdependence on large CDMOs and delayed engagement can increase development costs by up to 40% and slow clinical progress
Company launches clinical study of AI-designed oral formulation following MHRA approval, marking a major milestone in AI-driven drug development.
The platform created by NIT Rourkela researchers is capable of delivering rapid, accurate, and repeatable imaging results with minimal human intervention
The device screens for conditions like diabetic retinopathy, glaucoma, age-related macular degeneration, cataract and refractive error, in under ten minutes per patient
The company is set to unveil new clinical data across obesity, diabetes, kidney, and liver disease programs
On a full-year basis, revenue from operations for FY26 grew 18.9 percent year-on-year to Rs 827.87 crore compared to Rs 696.48 crore in FY25
PAT soars 201%, EBITDA up 88% on strong PHPO demand & margin expansion
For the full year, standalone gross revenue crossed Rs. 1,700 crore
The finance leader and investment banking veteran to steer global financial strategy, investor relations, and growth initiatives
Lilly will acquire Curevo in a deal worth up to $1.5 billion in cash, including upfront and milestone-based payments.
Subscribe To Our Newsletter & Stay Updated